Related Experiment Video

Updated: Jun 14, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent

Anthony H Barnett1

  • 1University of Birmingham and Heart of England NHS Foundation Trust, Birmingham, UK. anthony.barnett@heartofengland.nhs.uk

Current Medical Research and Opinion
|April 8, 2010
PubMed
Abstract

Insights

For type 2 diabetes management, metformin, thiazolidinediones, and DPP-4 inhibitors are recommended oral agents to minimize hypoglycemia risk. Early attention to hypoglycemia is crucial for long-term glucose control success.

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes patients initially have low hypoglycemia risk, but beta-cell dysfunction increases vulnerability over time.
  • Severe hypoglycemia poses significant morbidity and mortality risks, hindering glycemic control and diabetes complication prevention.
  • Balancing glycemic control with low hypoglycemia risk is essential for optimal type 2 diabetes patient care.

Purpose of the Study:

  • To review oral antidiabetic agents and their association with hypoglycemia.
  • To identify oral agents that best balance glycemic control with a low risk of hypoglycemia.

Main Methods:

  • Literature search of Embase and Medline databases (1998-2009).
  • Keywords included specific oral agents (DPP-4 inhibitors, metformin, sulfonylureas, thiazolidinediones) and hypoglycemia.
  • Retrospective narrative review of selected publications.

Main Results:

  • Metformin, thiazolidinediones, and DPP-4 inhibitors demonstrate a low propensity for causing hypoglycemia, especially in monotherapy or combination.
  • Failure to manage early hypoglycemia can compromise long-term treatment efficacy.

Conclusions:

  • Metformin, thiazolidinediones, and DPP-4 inhibitors are the preferred oral agents for minimizing hypoglycemia risk.
  • Integrating proactive hypoglycemia management into long-term glucose control strategies is vital.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...